Medication info
Nanomet XR Extended-Release Tablets 50/500 mg

Nanomet XR Extended-Release Tablets 50/500 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Korea Hutech Pharmaceutical Co., Ltd.
Appearance
Light blue, oval-shaped, bilaterally convex extended-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202201879 · Approved 2022.05.09 · Insurance code 649105520

This product's status changed to Approval withdrawn on 2026.02.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this product should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this product must be swallowed whole and should not be split, crushed, ground, or chewed. The 100/1000 mg extended-release tablet of this product is taken once daily, 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets of this product take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product. 2. Patients receiving metformin: - The recommended initial dose of this product for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching to this product from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this product's 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this product. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this product must be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Korea Hutech Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes when taken in combination with sitagliptin and metformin. It is effective in improving blood sugar management alongside diet and exercise regimens. Hence, this medication assists in blood sugar control for patients with type 2 diabetes.

How to take

Adult dose

In antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this product should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this product must be swallowed whole and should not be split, crushed, ground, or chewed. The 100/1000 mg extended-release tablet of this product is taken once daily, 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets of this product take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this product is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this product. 2. Patients receiving metformin: - The recommended initial dose of this product for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching to this product from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. - Patients receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this product's 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is a total daily dose of sitagliptin 100 mg, and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this product. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this product must be discontinued immediately. Patients with hepatic impairment This product should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains sitagliptin and metformin and is used for the treatment of diabetes. Firstly, sitagliptin can cause rare but serious hypersensitivity reactions, so if an allergic reaction is suspected, discontinuation should occur immediately and a consultation with a physician is advised. Furthermore, acute pancreatitis may occur, thus careful observation is required if symptoms such as abdominal pain or vomiting arise, and discontinuation should happen if necessary. Metformin can cause a serious side effect known as lactic acidosis, which carries a higher risk in specific situations such as impaired kidney function, liver dysfunction, severe dehydration, or serious infections. Thus, patients with poor kidney function or acute illnesses should avoid using this medication. This medication is not to be administered to those with moderate or severe renal impairment, acute heart failure, acute myocardial infarction, sepsis, pregnant or breastfeeding women, as well as type 1 diabetes patients. When taking this medication, awareness of symptoms of hypoglycemia is critical, and particularly when prescribed alongside other hypoglycemic agents or insulin, the risk of hypoglycemia may increase necessitating frequent blood sugar checks. This medication is not recommended for patients with impaired liver function, and regular blood tests to monitor kidney function should be conducted for any abnormalities. Additionally, since alcohol consumption can elevate the risk of lactic acidosis, excessive drinking should be avoided during the course of this medication. If undergoing surgery or tests using contrast agents, this medication should be discontinued for a certain period, and reinitiated only after confirming normal kidney function. Elderly patients are at higher risk of reduced kidney function and may require dose adjustments and regular testing. During the use of this medication, it is essential to maintain a consistent dietary regimen and exercise, and to immediately consult a healthcare professional in case of unusual symptoms.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 16 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, thus should be stored in a tightly sealed container. The recommended storage temperature is at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness safely for a longer duration.

Appearance and packaging

Appearance

Light blue, oval-shaped, bilaterally convex extended-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.